Dimerix Limited (ASX:DXB)
Australia · Delayed Price · Currency is AUD 0.5150
-0.0100 (-1.90%)
Feb 5, 2026, 4:10 PM AEST
Dimerix Revenue
In the fiscal year ending June 30, 2025, Dimerix had annual revenue of 5.59M AUD with 1,271.12% growth. Dimerix had revenue of 5.30M in the half year ending June 30, 2025, with 14,305.57% growth.
Revenue
5.59M
Revenue Growth
+1,271.12%
P/S Ratio
55.35
Revenue / Employee
n/a
Employees
n/a
Market Cap
309.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.59M | 5.18M | 1,271.12% |
| Jun 30, 2024 | 407.47K | 370.68K | 1,007.64% |
| Jun 30, 2023 | 36.79K | -6.43M | -99.43% |
| Jun 30, 2022 | 6.46M | 2.02M | 45.58% |
| Jun 30, 2021 | 4.44M | 2.10M | 89.65% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Clinuvel Pharmaceuticals | 95.02M |
| Orthocell | 7.55M |
| Recce Pharmaceuticals | 7.51M |
| Racura Oncology | 6.04M |
| Starpharma Holdings | 5.85M |
| Botanix Pharmaceuticals | 5.79M |
| Actinogen Medical | 5.49M |
| Immutep | 5.04M |
Dimerix News
- 7 weeks ago - Dimerix Completes Enrolment In Phase 3 Trial Of DMX-200 In Focal Segmental Glomerulosclerosis - Nasdaq
- 10 months ago - Biotech Dimerix lands $940m licensing deal for kidney drug sales - The Australian Financial Review